Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoid neoplasms occurring as a result of immunosuppression following both solid organ and hematopoietic cell transplant (HCT). PTLD have a variety of presentations and only recently have been described to present as an isolated EBV-associated mucocutaneous ulceration (MCU). To our knowledge, only one case of PTLD manifesting as EBV+ MCU has been reported following HCT. 1 Here we report a second case and provide diagnostic consideration and management recommendations.
A 64-year-old Caucasian male with advanced mantle cell lymphoma underwent high-dose therapy (HDT) and autologous HCT in first remission. Three years after high-dose therapy, the patient developed therapy-related myelodysplastic syndrome. He subsequently underwent a HLA-identical sibling allogeneic HCT after reduced intensity conditioning with fludarabine and busulfan. GVHD prophylaxis consisted of methotrexate and tacrolimus.
At day +60 following allografting, the patient reported otalgia associated with a right sided oral ulceration. His tacrolimus level was therapeutic at that time with an FK506 level of 9.1 ng/ml. On examination, he was found to have a 2 × 2 cm 2 right buccal mucosal ulcer covered with a white exudate. There was no purulent drainage and no other oral lesions or associated lymphadenopathy. A positron emission tomography scan showed no hypermetabolic activity. The mucosal ulcer did not respond to empiric antibiotics prompting an incisional biopsy for histopathological evaluation.
Hematoxylin and eosin-stained sections of the biopsy specimen demonstrated ulcerated mucosa with underlying salivary glands ( Figure 1a ). An atypical inflammatory infiltrate was present superficial to the ulceration and consisted of a heterogeneous lymphoid infiltrate admixed with histiocytes and neutrophils. The dominant cell population consisted of small-to-medium-sized lymphocytes with elongated nuclei, mild nuclear irregularity, coarse chromatin and moderate amounts of pale cytoplasm. These cells were admixed with lesser numbers of large immunoblast-like cells and Reed Sternberg-like cells. The larger lymphocyte population had highly irregular, frequently reniform nuclei with large amounts of cytoplasm and prominent nucleoli. These large atypical cells were primarily positive for CD20 (weak to strong), PAX-5 (weak to strong) and CD79a by immunohistochemistry and lacked any T-cell antigen expression ( Figure 2 ). The Reed Sternberg-like subset showed positivity for CD30, PAX-5 (weak) and CD45 and was negative for CD15 ( Figure 1b) . The background smaller lymphocytes were predominately CD8+ T cells with fewer admixed CD4+ T cells. An EBV in situ hybridization study was positive in a mixture of the lymphocytes, including small, medium and large forms (Figure 2 ). The final pathological diagnosis was an EBV+ lymphoproliferative disorder, sub-classified as an EBV+ MCU.
Before HCT, the patient was EBV IgG seropositive. At the time of diagnosis of EBV+ MCU, the patient had no detectible EBV DNA in peripheral blood by quantitative real-time PCR (assay range of 100-1 × 10 6 copies/mL). The patient's immunosuppression regimen at time of diagnosis included tacrolimus 1 mg every morning and 0.5 mg every evening. After diagnosis, the dose was decreased to 0.5 mg twice daily for the first 3 weeks and subsequently decreased further to 0.5 mg daily in the next 4 weeks. This approximate 33% reduction in immunosuppression resulted in complete resolution of the MCU in the first 3 weeks, with no subsequent relapse.
The World Health Organization classifies PTLDs into early lesions, polymorphic PTLD and monomorphic PTLD. 2 Risk factors for PTLD in HCT recipients include T-cell depletion, unrelated or HLA-mismatched donors and donor/recipient EBV serostatus. 3, 4 The incidence of PTLD following allogeneic HCT is greatest within 1 year with a steep decline afterward. The histological differential diagnosis of EBV+ MCU includes polymorphic and monomorphic PTLDs. In the current case, the polymorphous nature of the lymphoid infiltrate on hematoxylin and eosin may suggest a polymorphic PTLD; however, the immunohistochemistry revealed that the atypical large-sized B cells were few in number, while the T cells comprised the polymorphous, reactive background. Polymorphic PTLDs are B-cell lymphoproliferative disorders wherein the neoplastic B cells have heterogeneous morphology, rather than the inflammatory milieu. EBV+ MCU can also be mistaken for monomorphic PTLD. For example, in our case many of the histological and immunohistochemical features mimicked a classical Hodgkin lymphoma (cHL)-namely, Reed Sternberg-like cells showing CD30 and PAX-5 expression and a dense, T-cell-rich inflammatory background. However, not all the atypical cells were Reed Sternberg-like and the immunophenotype was not classic for cHL, given the CD45 expression and CD15 negativity. Ultimately, in our case, the EBV stain was most informative, as it allowed categorization into an EBV-positive lymphoproliferative disorder. The clinical setting of an isolated mucosal lesion combined with the histological features mimicking cHL allowed further classification as an EBV+ MCU. The development of PTLD has previously been shown to correlate with EBV viremia. 6 In contrast, our patient did not have a detectable EBV viral load by PCR despite a positive EBV in situ hybridization study on biopsy. Negative EBV viral loads, in fact, are characteristic for EBV+ MCU.
The differential diagnosis of an oral ulceration in the post-HCT patient is broad and includes bacterial infection, oral mucosal GVHD and oral squamous cell carcinoma. Oral EBV+ PTLD has previously been described in the post HCT patient presenting as an oral mass however presentation as an oral ulceration is rare. 7 EBV+ MCU is a recently descripted histological entity. 8 It presents as a solitary lesion in the oral cavity, skin or gastrointestinal tract typically without additional sites of disease or bone marrow involvement. The majority of previously reported cases have mainly been associated with age-related immunosuppression in the context of solid organ transplantation. 1, 9 EBV+ MCUs usually follow a benign course and result in complete recovery. 8 Owing to the paucity of EBV+ MCU following allogeneic HCT, high index of suspicion and expert hematopathological review in patients presenting with solitary mucocutaneous lesions is warranted. We recommend immunosuppression taper as the preferred therapy option in the post-allogeneic HCT setting. Among patients not on any immunosuppression or ones not responding to reduction in immunosuppression, localized therapies (for example, radiotherapy) should be considered. Although anecdotal reports suggest responses following therapy with rituximab in combination with chemotherapy, such systemic options should be reserved for cases not responding to reduction in immunosuppression or localized therapy. 1 No reports of managing EBV+ MCU with surgical excision or single rituximab are available. Rare cases of EBV+ MCU progressing to cHL have been reported, underscoring meticulous follow-up of these cases to ensure complete clinical resolution. 10 In conclusion, PTLD presenting as EBV+ MCU represents a recently described, distinct clinical entity, which is rare among HCT recipients. Reduction in immunosuppression typically leads to resolution in most cases. This entity should be considered in the differential diagnosis of a single ulcerative mucocutaneous lesion in these immunosuppressed patients.
